Truist raises Septerna stock price target to $43 on hypoparathyroidism outlook

Truist raises Septerna stock price target to $43 on hypoparathyroidism outlook

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.